Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Front Pharmacol · 2021 · PMC8819690 · PMID 35140610

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Assessment of the association of muscarinic cholinergic receptor 1 (CHRM1) and 2 (CHRM2) genetic variability with TD development showed a trend towards CHRM2 rs2061174 and rs1824024 effect on TD risk ( Boiko et al., 2020 ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Schizophrenia patients with the DRD1 rs4532 CC genotype had increased chance for TD development, while the rest of the studied polymorphisms did not reach statistical significance ( Lai et al., 2011b ).

also in 111,027 other papers

nominally significantno p-value reported

The investigation of copy number variations of the long (L) and short (S) forms of C4A and C4B in Europeans has shown a nominally significant association between C4BL and TD severity ( Zai et al., 2019b ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.